STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing ® stent to treat Acute Myocardial Infarction (AMI), today announced its revenues for third-quarter 2013 and 9-months through September 30, 2013.
- Trends in quarterly and 9-month 2013 revenues*
|9 months||Quarterly - 3 months|
|€ thousands||9 months2013||9 months2012||%change||Q3 2013||Q3 2012||%change|
|* Data reviewed by statutory auditors|
Over the first nine months of the financial year, STENTYS recorded revenues of €2.4 million, up 32% compared to the same period in 2012.
- Healthy cash position
- Presentation of new clinical results at the TCT conference
- Upcoming financial results